Bellevue Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bellevue Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-111	Closed	-$2K	–	603
2021 Q3	$2K	Hold	111	–	–	﹤0.01%	555
2021 Q2	$1K	Sell	111 -11	-9%	-$104	﹤0.01%	582
2021 Q1	$1K	Sell	122 -22	-15%	-$272	﹤0.01%	639
2020 Q4	$2K	Buy	+144	New	+$2.08K	﹤0.01%	617

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Bellevue Asset Management's TRIL Position: Q4 2021 in Review

Bellevue Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 111 shares — an estimated $2K sold.

Bellevue Asset Management first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Bellevue Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Bellevue Asset Management sold 111 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2K.
Bellevue Asset Management first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Bellevue Asset Management's Trillium Therapeutics Inc. position peaked at $2K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Bellevue Asset Management's 13F filing for Q4 2021, filed 3 Feb 2022.